Publication:
Human Immunodeficiency Virus/Hepatits C Virus Coinfection in Spain: Elimination Is Feasible, but the Burden of Residual Cirrhosis Will Be Significant

Simple item page
dc.contributor.authorBerenguer, Juan
dc.contributor.authorJarrin, Inmaculada
dc.contributor.authorPerez-Latorre, Leire
dc.contributor.authorHontanon, Victor
dc.contributor.authorVivancos, Maria J
dc.contributor.authorNavarro, Jordi
dc.contributor.authorTellez, Maria J
dc.contributor.authorGuardiola, Josep M
dc.contributor.authorIribarren, Jose A
dc.contributor.authorRivero-Juarez, Antonio
dc.contributor.authorMarquez, Manuel
dc.contributor.authorArtero, Arturo
dc.contributor.authorMorano, Luis
dc.contributor.authorSantos, Ignacio
dc.contributor.authorMoreno, Javier
dc.contributor.authorFarinas Alvarez, Carmen
dc.contributor.authorGalindo, Maria
dc.contributor.authorHernando, Maria A
dc.contributor.authorMontero, Marta
dc.contributor.authorCifuentes Luna, Carmen
dc.contributor.authorDomingo, Pere
dc.contributor.authorSanz, Jose
dc.contributor.authorDomingez, Lourdes
dc.contributor.authorFerrero Beneitez, Oscar Luis
dc.contributor.authorde la Fuente, Belen
dc.contributor.authorRodriguez, Carmen
dc.contributor.authorReus, Sergio
dc.contributor.authorHernandez-Quero, Jose
dc.contributor.authorGaspar, Gabriel
dc.contributor.authorPerez-Martinez, Laura
dc.contributor.authorGarcia, Coral
dc.contributor.authorForce, Lluis
dc.contributor.authorVeloso, Sergio
dc.contributor.authorLosa, Juan E
dc.contributor.authorVilaro, Josep
dc.contributor.authorBernal, Enrique
dc.contributor.authorArponen, Sari
dc.contributor.authorOrti, Amat J
dc.contributor.authorChocarro, Angel
dc.contributor.authorTeira, Ramon
dc.contributor.authorAlonso, Gerardo
dc.contributor.authorSilvarino, Rafael
dc.contributor.authorVegas, Ana
dc.contributor.authorGeijo, Paloma
dc.contributor.authorBisbe, Josep
dc.contributor.authorEsteban, Herminia
dc.contributor.authorGonzalez-Garcia, Juan
dc.contributor.authorGeSIDA 8514 Study Grp
dc.date.accessioned2024-09-06T09:56:43Z
dc.date.available2024-09-06T09:56:43Z
dc.date.issued2018-01
dc.description.abstractBackground. We assessed the prevalence of antibodies against hepatitis C virus (HCV-Abs) and active HCV infection in patients infected with human immunodeficiency virus (HIV) in Spain in 2016 and compared the results with those of similar studies performed in 2002, 2009, and 2015. Methods. The study was performed in 43 centers during October-November 2016. The sample was estimated for an accuracy of 2% and selected by proportional allocation and simple random sampling. During 2016, criteria for therapy based on direct-acting antiviral agents (DAA) were at least significant liver fibrosis, severe extrahepatic manifestations of HCV, and high risk of HCV transmissibility. Results. The reference population and the sample size were 38 904 and 1588 patients, respectively. The prevalence of HCV-Abs in 2002, 2009, 2015, and 2016 was 60.8%, 50.2%, 37.7%, and 34.6%, respectively (P trend <.001, from 2002 to 2015). The prevalence of active HCV in 2002, 2009, 2015, and 2016 was 54.0%, 34.0%, 22.1%, and 11.7%, respectively (P trend <.001). The anti-HCV treatment uptake in 2002, 2009, 2015, and 2016 was 23.0%, 48.0%, 59.3%, and 74.7%, respectively (P trend <.001). In 2016, HCV-related cirrhosis was present in 7.6% of all HIV-infected individuals, 15.0% of patients with active HCV, and 31.5% of patients who cleared HCV after anti-HCV therapy. Conclusions. Our findings suggest that with universal access to DAA-based therapy and continued efforts in prevention and screening, it will be possible to eliminate active HCV among HIV-infected individuals in Spain in the short term. However, the burden of HCV-related cirrhosis will continue to be significant among HIV-infected individuals.en
dc.description.sponsorshipThis work was funded by grant Ref. no. GLD14-00279 from the GILEAD Fellowship Programme (Spain) and by the Spanish AIDS Research Network (RD16/0025/0017, RD16/0025/0018) that is included in the Spanish I+D+I Plan and is co-financed by ISCIII-Subdireccion General de Evaluacion and European Funding for Regional Development (FEDER).es_ES
dc.format.number1es_ES
dc.format.pageofx258es_ES
dc.format.volume5es_ES
dc.identifier.citationBerenguer J, Jarrin I, Perez-Latorre L, Hontanon V, Vivancos MJ, Navarro J, et al. Human Immunodeficiency Virus/Hepatits C Virus Coinfection in Spain: Elimination Is Feasible, but the Burden of Residual Cirrhosis Will Be Significant. Open Forum Infect Dis. 2018 Jan;5(1):ofx258.en
dc.identifier.doi10.1093/ofid/ofx258
dc.identifier.issn2328-8957
dc.identifier.journalOpen Forum Infectious Diseaseses_ES
dc.identifier.otherhttp://hdl.handle.net/20.500.13003/10788
dc.identifier.pubmedID29354658es_ES
dc.identifier.puiL624102428
dc.identifier.scopus2-s2.0-85050217633
dc.identifier.urihttps://hdl.handle.net/20.500.12105/22631
dc.identifier.wos423832400014
dc.language.isoengen
dc.publisherOxford University Pressen
dc.relation.publisherversionhttps://dx.doi.org/10.1093/ofid/ofx258en
dc.rights.accessRightsopen accessen
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectcoinfection/epidemiology
dc.subjecthepatitis C/drug therapy/epidemiology
dc.subjectHIV infection/epidemiology
dc.subjectSpain/epidemiology
dc.titleHuman Immunodeficiency Virus/Hepatits C Virus Coinfection in Spain: Elimination Is Feasible, but the Burden of Residual Cirrhosis Will Be Significanten
dc.typeresearch articleen
dspace.entity.typePublication
relation.isAuthorOfPublication831dbac1-fcb6-444a-90e1-4b562eecb934
relation.isAuthorOfPublication.latestForDiscovery831dbac1-fcb6-444a-90e1-4b562eecb934
Files
Collections
IdisBa - Instituto de Investigación Sanitaria Illes Balears (Baleares)
i+12 - Instituto de Investigación Hospital 12 de Octubre (Madrid)
IdiPAZ - Instituto de Investigación Sanitaria Hospital La Paz (Madrid)
IiSGM - Instituto de Investigación Sanitaria Gregorio Marañón (Madrid)
IMIBIC - Instituto Maimónides de Investigación Biomédica de Córdoba (Andalucía)